CD19 and acute lymphoblastic leukemia: CD19 CAR-T cells have produced promising outcomes in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), with complete remission (CR) rates as high as 90% and deep molecular responses in patients with relapsing/refractory (r/r) disease8,9.